2023 World Conference on Lung Cancer (Posters)-EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe

EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted to examine the real-world treatment patterns and outcomes in European patients with metastatic non-small cell lung cancer (mNSCLC) who had progressed on platinum-doublet chemotherapy and anti-PD(L)1 therapy. The study aimed to assess overall survival (OS), real-world time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) in this population.<br /><br />The study included European patients with mNSCLC who had progressed on therapy with one anti-PD(L)1 and platinum-doublet chemotherapy regimen and had initiated a subsequent line of therapy between June 1st, 2017 and November 30th, 2021. Data from patient charts were collected through a physician panel-based medical chart review.<br /><br />The study found that the most common treatment regimens observed after progression on platinum-doublet chemotherapy and anti-PD(L)1 were non-platinum chemotherapy, non-platinum chemotherapy with VEGF(R) inhibitors, and platinum-doublet chemotherapy. The median overall survival was shorter than one year, indicating an unmet clinical need for more efficacious therapies for this patient population.<br /><br />The study had some limitations, including the collection of de-identified data through a physician panel, which may limit the generalizability of the findings to the overall practice of oncologists/pulmonologists. Additionally, the study focused on patients from Germany, France, and the United Kingdom, so the findings may not be generalizable to patients outside of these countries.<br /><br />In conclusion, this study provides real-world data on treatment patterns and outcomes in European patients with mNSCLC who had progressed on platinum-doublet chemotherapy and anti-PD(L)1 therapy. The findings highlight the need for more effective treatment options for patients in this population.

Asset Subtitle

Ticiana Leal

Meta Tag

Speaker Ticiana Leal

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

real-world treatment patterns

metastatic non-small cell lung cancer

platinum-doublet chemotherapy

anti-PD(L)1 therapy

overall survival

time-to-treatment discontinuation

progression-free survival

treatment regimens

efficacious therapies